GE11-PDA-Pt@USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy

Yang, Chengcheng; Mi, Xuan; Su, Huilan; Yang, Jingxing; Gu, Yonggen; Zhang, Lu; Sun, Wenshe; Liang, Xiaowen; Zhang, Chunfu

doi:10.1039/c8bm01492b

Cited by 36 publications

(41 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vivo biodistribution of nanoparticles (% ID g −1 ) was determined following PAI by the quantification of iron content in different organs by using inductively coupled plasma mass spectrometry (ICP‐MS). The nanoparticles were mainly captured by the reticuloendothelial system in the liver and spleen, consistent with the in vivo behaviors of most nanoparticles previously reported; [ 22 ] however, HA coating significantly improved the tumor accumulation efficiency of PDA@Fe 3 O 4 (Figure S4a, Supporting Information). Tumor retention of HA‐PDA@Fe 3 O 4 was further assessed by monitoring the changes in PAI signal intensity of tumors; the tumor accumulation of HA‐PDA@Fe 3 O 4 increased with time, culminated at 24 h after injection, and then declined (Figure S4b, Supporting Information).…”

Section: Resultssupporting

confidence: 88%

A Nano “Immune‐Guide” Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy

Sun

Yang

Hou

et al. 2021

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

Artificially modulating the type, density, and location of immune cells within the tumor microenvironment can suppress tumor growth and efficiently promote current immunotherapy. In this study, a magnetite nanoparticle‐based “immune‐guide” is developed by the functionalization of magnetite nanoparticles with hyaluronic acid (HA). HA, an extracellular matrix component, can target various CD44‐overexpressing tumors and mediate the adhesion and migration of multiple types of immune cells. Thus, HA‐functionalized magnetite nanoparticles (HA‐PDA@Fe3O4) can highly efficiently accumulate in breast cancer and penetrate deep into the tumor parenchyma. Consequently, high intratumoral concentration of HA, serving as a “guidepost,” can directly recruit lymphocytes and elicit more chemokine production through cascading amplification effects, turning the immune “cold” tumor into a “hot” one. More importantly, HA‐PDA@Fe3O4 can effectively remodel the diversity, origin, and activation of tumor‐associated macrophages by recruiting and activating infiltrating macrophages, while simultaneously reducing the M2‐maintained tissue‐resident macrophages. Thus, HA‐PDA@Fe3O4 synergistically improves T cell‐ and macrophage‐based immunotherapies as well as interferes with the formation of premetastatic niches in the lung. By redistributing the localization of HA in tumors by using magnetite nanoparticles, this study provides a unique strategy to modulate the tumor immune microenvironment and potentiate tumor immunotherapies by using biocompatible nanomaterials without any therapeutic drug.

show abstract

Section: Resultssupporting

confidence: 88%

A Nano “Immune‐Guide” Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy

Sun

Yang

Hou

et al. 2021

Adv Funct Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…Iron (III) acetylacetonate (Fe(acac) 3 ≥ 97%) was purchased from Sigma-Aldrich Chemical Co. Ltd. (St Louis, MO, USA). The PAA-coated USPIO (PAA@USPIO) was synthesized using the polyol method according to previous report [24]. Briefly, poly (acrylic acid) (PAA, 50 wt%, solution in water, MW 1000, Acros, 8 mmol) and anhydrous ferric chloride (FeCl 3 , 4 mmol) were dissolved in 30 mL of DEG (diethylene glycol) and heated in a microwave under vigorous stirring.…”

Section: Methodsmentioning

confidence: 99%

18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts

et al. 2019

View full text Add to dashboard Cite

Purpose To develop a novel fluorine-18 (18F)-labeled arginine–glycine–aspartic acid (RGD)-coupled ultra-small iron oxide nanoparticle (USPIO) (hereafter, referred to as 18F-RGD@USPIO) and conduct an in-depth investigation to monitor the anti-angiogenic therapeutic effects by using a novel dual-modality PET/MRI probe. Methods The RGD peptide and 18F were coupled onto USPIO by click chemistry. In vitro experiments including determination of stability, cytotoxicity, cell binding of the obtained 18F-RGD@USPIO were carried out, and the targeting kinetics and bio-distribution were tested on an MDA-MB-231 tumor model. A total of 20 (n = 10 per group) MDA-MB-231 xenograft-bearing mice were treated with bevacizumab or placebo (intraperitoneal injections of bevacizumab or a volume-equivalent placebo solution at the dose of 5 mg/kg for consecutive 7 days, respectively), and underwent PET/CT and MRI examinations with 18F-RGD@USPIO before and after treatment. Imaging findings were validated by histological analysis with regard to β3-integrin expression (CD61 expression), microvascular density (CD31 expression), and proliferation (Ki-67 expression). Results Excellent stability, low toxicity, and good specificity to endothelial of 18F-RGD@USPIO were confirmed. The best time point for MRI scan was 6 h post-injection. No intergroup differences were observed in tumor volume development between baseline and day 7. However, 18F-RGD@USPIO binding was significantly reduced after bevacizumab treatment compared with placebo, both on MRI (P < 0.001) and PET/CT (P = 0.002). Significantly lower microvascular density, tumor cell proliferation, and integrin β3 expression were noted in the bevacizumab therapy group than the placebo group, which were consistent with the imaging results. Conclusion PET/MRI with the dual-modality nanoprobe, 18F-RGD@USPIO, can be implemented as a noninvasive approach to monitor the therapeutic effects of anti-angiogenesis in breast cancer model in vivo.

show abstract

“…Other common metal types with nanoradiosensitization effects include common non-high Z nanoradiosensitizers, such as nanoradiosensitizers, iron nanoradiosensitizers, and copper nanoradiosensitizers. Chengcheng Yang developed a polydopamine (PDA) coated Ge11 peptide conjugated iron oxide nanoparticles (Ge 11 -PDA-Pt@USPIOs) with cisplatin as a carrier, based on ultra-small superparamagnetic iron oxide nanoparticles (PAA@USPIos) coated with polyacrylic acid, showing synergistic therapeutic effects of radiotherapy and chemotherapy under low temperature in vitro ( 111 ). Muhammed prepared SiO-MNP-coated iron oxide nanoparticles by co-precipitation and other methods to enhance the radiation sensitization effect by increasing the production of ROS ( 112 ).…”

Section: The Main Types Of Nano-radiosensitizers In the Treatment Of mentioning

confidence: 99%

Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma

et al. 2021

View full text Add to dashboard Cite

Glioma is the most common intracranial malignant tumor, and its specific pathogenesis has been unclear, which has always been an unresolved clinical problem due to the limited therapeutic window of glioma. As we all know, surgical resection, chemotherapy, and radiotherapy are the main treatment methods for glioma. With the development of clinical trials and traditional treatment techniques, radiotherapy for glioma has increasingly exposed defects in the treatment effect. In order to improve the bottleneck of radiotherapy for glioma, people have done a lot of work; among this, nano-radiosensitizers have offered a novel and potential treatment method. Compared with conventional radiotherapy, nanotechnology can overcome the blood–brain barrier and improve the sensitivity of glioma to radiotherapy. This paper focuses on the research progress of nano-radiosensitizers in radiotherapy for glioma.

show abstract

GE11-PDA-Pt@USPIOs nano-formulation for relief of tumor hypoxia and MRI/PAI-guided tumor radio-chemotherapy

Abstract: GE11-PDA-Pt@USPIOs can relieve tumor hypoxic conditions efficiently and are highly effective for radio-chemotherapy of EGFR-positive tumors.

Cited by 36 publications

References 61 publications

A Nano “Immune‐Guide” Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy

A Nano “Immune‐Guide” Recruiting Lymphocytes and Modulating the Ratio of Macrophages from Different Origins to Enhance Cancer Immunotherapy

18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts

Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma

Contact Info

Product

Resources

About